Alpha synuclein SMART molecule - ICB International/CRCHUS

Drug Profile

Alpha synuclein SMART molecule - ICB International/CRCHUS

Alternative Names: a-Syn SMART Molecule; a-Syn-SM

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ICB International
  • Developer Centre de recherche du Centre hospitalier universitaire de Sherbrooke; ICB International
  • Class
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 05 Dec 2017 ICB International applies for Orphan Drug status in Multiple spinal atrophy in USA
  • 01 Jun 2017 Preclinical trials in Parkinson's disease in USA (Parenteral)
  • 08 Jul 2016 Preclinical development is ongoing in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top